Acadia Pharmaceuticals (ACAD) Stock: Why It's Up Today
Updated Oct 20, 2026, 1:16 PM ET · intraday price
- Trading at $20.26 as of 1:16 PM ET, +2.32% vs the prior close of $19.80.
- Volume 529.19K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)
ACAD rises 2.3% to $20.26. Trading at $20.26 (intraday, 1:16 PM ET), +2.32% vs the prior close of $19.80. Day range $19.86–$20.34, opened at $20.01.
ACAD daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — ACAD rises 2.3% to $20.26
- Trading at $20.26 (intraday, 1:16 PM ET), +2.32% vs the prior close of $19.80. Day range $19.86–$20.34, opened at $20.01.
- Volume was 529.19K shares, 0.3x its 50-day average of 1.88M — lighter than usual.
- Price is -19.5% vs its 50-day average ($25.18) and -15.4% vs its 200-day average ($23.94).
- 52-week range $18.39–$30.96; the current price sits at 15% of that range, 34.6% below the 52-week high.
Oct 19, 2026 — ACAD jumps 3.6% to $19.80
- Closed at $19.80, +3.56% vs the prior close of $19.12. Day range $19.11–$19.84, opened at $19.33.
- Volume was 1.30M shares, 0.7x its 50-day average of 1.89M.
- Price is -21.9% vs its 50-day average ($25.36) and -17.4% vs its 200-day average ($23.97).
- 52-week range $18.39–$30.96; today's close sits at 11% of that range, 36.0% below the 52-week high.
Oct 16, 2026 — ACAD dips 3.0% to $19.12
- Closed at $19.12, -2.99% vs the prior close of $19.71. Day range $18.87–$19.76, opened at $19.76.
- Volume was 1.67M shares, 0.9x its 50-day average of 1.92M.
- Price is -25.2% vs its 50-day average ($25.55) and -20.4% vs its 200-day average ($24.01).
- 52-week range $18.39–$30.96; today's close sits at 6% of that range, 38.2% below the 52-week high.
Oct 15, 2026 — ACAD rises 2.4% to $19.71
- Closed at $19.71, +2.39% vs the prior close of $19.25. Day range $19.28–$19.88, opened at $19.48.
- Volume was 1.77M shares, 0.9x its 50-day average of 1.97M.
- Price is -23.4% vs its 50-day average ($25.74) and -18.0% vs its 200-day average ($24.04).
- 52-week range $18.39–$30.96; today's close sits at 11% of that range, 36.3% below the 52-week high.
Oct 14, 2026 — ACAD jumps 3.4% to $19.25
- Closed at $19.25, +3.38% vs the prior close of $18.62. Day range $18.49–$19.28, opened at $18.60.
- Volume was 1.64M shares, 0.8x its 50-day average of 1.99M.
- Price is -25.7% vs its 50-day average ($25.92) and -20.1% vs its 200-day average ($24.08).
- 52-week range $18.39–$30.96; today's close sits at 7% of that range, 37.8% below the 52-week high.
Oct 13, 2026 — ACAD slides 4.1% to $18.62, a 52-week low
- Closed at $18.62, -4.07% vs the prior close of $19.41. Day range $18.39–$19.10, opened at $19.05.
- Volume was 2.14M shares, 1.1x its 50-day average of 1.97M.
- Price is -28.6% vs its 50-day average ($26.08) and -22.8% vs its 200-day average ($24.12).
- 52-week range $18.39–$30.96; today's close sits at 2% of that range, 39.9% below the 52-week high.
Oct 12, 2026 — ACAD dips 1.9% to $19.41, a 52-week low
- Closed at $19.41, -1.87% vs the prior close of $19.78. Day range $19.40–$19.87, opened at $19.70.
- Volume was 1.18M shares, 0.6x its 50-day average of 1.98M — lighter than usual.
- Price is -26.0% vs its 50-day average ($26.22) and -19.7% vs its 200-day average ($24.17).
- 52-week range $19.32–$30.96; today's close sits at 1% of that range, 37.3% below the 52-week high.
Oct 9, 2026 — ACAD rises 1.0% to $19.78
- Closed at $19.78, +1.02% vs the prior close of $19.58. Day range $19.58–$20.05, opened at $19.60.
- Volume was 1.47M shares, 0.7x its 50-day average of 1.98M.
- Price is -24.9% vs its 50-day average ($26.34) and -18.3% vs its 200-day average ($24.21).
- 52-week range $19.32–$30.96; today's close sits at 4% of that range, 36.1% below the 52-week high.
Oct 8, 2026 — ACAD dips 0.4% to $19.58, a 52-week low, 3 down days in a row
- Closed at $19.58, -0.36% vs the prior close of $19.65. Day range $19.32–$19.79, opened at $19.46.
- Volume was 2.01M shares, 1.0x its 50-day average of 1.97M.
- Price is -26.1% vs its 50-day average ($26.48) and -19.3% vs its 200-day average ($24.25).
- 52-week range $19.32–$30.96; today's close sits at 2% of that range, 36.8% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ACAD dips 0.5% to $19.65, a 52-week low
- Closed at $19.65, -0.46% vs the prior close of $19.74. Day range $19.46–$19.80, opened at $19.60.
- Volume was 1.78M shares, 0.9x its 50-day average of 1.95M.
- Price is -26.2% vs its 50-day average ($26.62) and -19.1% vs its 200-day average ($24.29).
- 52-week range $19.46–$30.96; today's close sits at 2% of that range, 36.5% below the 52-week high.
Oct 6, 2026 — ACAD dips 1.8% to $19.74, a 52-week low
- Closed at $19.74, -1.84% vs the prior close of $20.11. Day range $19.67–$20.36, opened at $20.16.
- Volume was 1.67M shares, 0.9x its 50-day average of 1.95M.
- Price is -26.2% vs its 50-day average ($26.74) and -18.9% vs its 200-day average ($24.33).
- 52-week range $19.57–$30.96; today's close sits at 1% of that range, 36.2% below the 52-week high.
Oct 5, 2026 — ACAD rises 0.8% to $20.11
- Closed at $20.11, +0.80% vs the prior close of $19.95. Day range $19.57–$20.45, opened at $20.05.
- Volume was 3.15M shares, 1.7x its 50-day average of 1.91M.
- Price is -25.1% vs its 50-day average ($26.86) and -17.5% vs its 200-day average ($24.36).
- 52-week range $19.57–$30.96; today's close sits at 5% of that range, 35.0% below the 52-week high.
Oct 2, 2026 — ACAD rises 0.3% to $19.95
- Closed at $19.95, +0.30% vs the prior close of $19.89. Day range $19.88–$20.24, opened at $20.01.
- Volume was 2.56M shares, 1.4x its 50-day average of 1.88M.
- Price is -26.0% vs its 50-day average ($26.95) and -18.2% vs its 200-day average ($24.40).
- 52-week range $19.59–$30.96; today's close sits at 3% of that range, 35.6% below the 52-week high.
ACAD bull case vs bear case (from the data)
- Annual revenue grew 11.9% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: profit of $391.00M.
- Price is -19.5% vs its 50-day average — short-term trend is down.
- Price is -15.4% vs its 200-day average — below the long-term trend line.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
ACAD latest news & SEC filings
Every SEC filing by or about ACAD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schneyer Mark C. sold 5,000 shares at $29.00 (≈$145.00K) on Aug 6, 2026
- Schneyer Mark C. sold 9,292 shares at $29.34 (≈$272.63K) on Aug 6, 2026
- Schneyer Mark C. sold 5,000 shares at $29.00 (≈$145.00K) on Aug 6, 2026
- Schneyer Mark C. sold 9,292 shares at $29.34 (≈$272.63K) on Aug 6, 2026
- Schneyer Mark C. sold 5,000 shares at $29.00 (≈$145.00K) on Aug 6, 2026
- Schneyer Mark C. sold 9,292 shares at $29.34 (≈$272.63K) on Aug 6, 2026
- …plus 6 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $307.96M (prior year $264.57M) (+16.4% vs Jun 30, 2025)
- Net income: $31.50M (prior year $26.67M) (+18.1% vs Jun 30, 2025)
- Diluted EPS: $0.18 (prior year $0.16) (+12.5% vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Thompson Elizabeth H.Z. sold 50 shares at $26.17 (≈$1.31K) on Jul 30, 2026
- Thompson Elizabeth H.Z. sold 16,508 shares at $26.13 (≈$431.35K) on Jul 30, 2026
- Thompson Elizabeth H.Z. sold 50 shares at $26.17 (≈$1.31K) on Jul 30, 2026
- Thompson Elizabeth H.Z. sold 16,508 shares at $26.13 (≈$431.35K) on Jul 30, 2026
- Thompson Elizabeth H.Z. sold 50 shares at $26.17 (≈$1.31K) on Jul 30, 2026
- Thompson Elizabeth H.Z. sold 16,508 shares at $26.13 (≈$431.35K) on Jul 30, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kihara James sold 11,421 shares at $26.08 (≈$297.86K) on Jun 26, 2026
- Kihara James sold 11,421 shares at $26.08 (≈$297.86K) on Jun 26, 2026
- Kihara James sold 11,421 shares at $26.08 (≈$297.86K) on Jun 26, 2026
- Kihara James sold 11,421 shares at $26.08 (≈$297.86K) on Jun 26, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 26, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade ACAD
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Jan 13, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.62% (largest 12.8%).
- Liquidity: about 2.31M shares (≈$46.81M) trade per day on average.
- 52-week position: $20.26 vs a range of $18.39–$30.96 (15% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Mark C. Schneyer sold 5,000 shares on Aug 6, 2026.
- Latest filings: 8-K Sep 24, 2026; 8-K Sep 11, 2026; 10-Q Aug 5, 2026.
- Share count: 172.31M shares outstanding (Jul 28, 2026), +2.1% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ACAD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 20.01 | 20.34 | 19.86 | 20.26 | 529.19K |
| Oct 19, 2026 | 19.33 | 19.84 | 19.11 | 19.80 | 1.30M |
| Oct 16, 2026 | 19.76 | 19.76 | 18.87 | 19.12 | 1.67M |
| Oct 15, 2026 | 19.48 | 19.88 | 19.28 | 19.71 | 1.77M |
| Oct 14, 2026 | 18.60 | 19.28 | 18.49 | 19.25 | 1.64M |
| Oct 13, 2026 | 19.05 | 19.10 | 18.39 | 18.62 | 2.14M |
| Oct 12, 2026 | 19.70 | 19.87 | 19.40 | 19.41 | 1.18M |
| Oct 9, 2026 | 19.60 | 20.05 | 19.58 | 19.78 | 1.47M |
| Oct 8, 2026 | 19.46 | 19.79 | 19.32 | 19.58 | 2.01M |
| Oct 7, 2026 | 19.60 | 19.80 | 19.46 | 19.65 | 1.78M |
| Oct 6, 2026 | 20.16 | 20.36 | 19.67 | 19.74 | 1.67M |
| Oct 5, 2026 | 20.05 | 20.45 | 19.57 | 20.11 | 3.15M |
| Oct 2, 2026 | 20.01 | 20.24 | 19.88 | 19.95 | 2.56M |
| Oct 1, 2026 | 19.95 | 20.19 | 19.59 | 19.89 | 2.73M |
| Sep 30, 2026 | 20.28 | 20.70 | 19.93 | 20.15 | 3.13M |
| Sep 29, 2026 | 20.61 | 20.61 | 20.06 | 20.22 | 2.51M |
| Sep 28, 2026 | 20.53 | 20.63 | 19.80 | 20.53 | 3.52M |
| Sep 25, 2026 | 22.21 | 22.21 | 20.61 | 20.68 | 3.36M |
| Sep 24, 2026 | 24.38 | 24.38 | 21.97 | 22.18 | 6.76M |
| Sep 23, 2026 | 26.41 | 26.51 | 24.93 | 25.43 | 1.31M |
About Acadia Pharmaceuticals
Acadia Pharmaceuticals (ACAD) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1070494.
ACAD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jun 2, 2026 |
| Bros. Advisors Lp Baker | Director | Jun 2, 2026 |
| Felix Baker | Director | Jun 2, 2026 |
| Julian Baker | Director | Jun 2, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Jun 2, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jun 2, 2026 |
| Laura Brege | Director | Jun 1, 2026 |
| James M Daly | Director | Jun 1, 2026 |
| Elizabeth A. Garofalo | Director | Jun 1, 2026 |
| Edmund Harrigan | Director | Jun 1, 2026 |
| Adora Ndu | Director | Jun 1, 2026 |
| Adams Catherine Owen | Chief Executive Officer | Mar 26, 2026 |
| Jonathan Poole | Director | Jun 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thomas Garner | EVP, Chief Commercial Officer | Mar 10, 2026 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | Jun 29, 2026 |
| Adams Catherine Owen | Chief Executive Officer | Mar 26, 2026 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Mar 26, 2026 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Aug 7, 2026 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | Jul 31, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 6, 2026 | Mark C. Schneyer | Sale | 5,000 | $29.00 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 9,292 | $29.34 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 5,000 | $29.00 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 9,292 | $29.34 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 5,000 | $29.00 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 9,292 | $29.34 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 5,000 | $29.00 |
| Aug 6, 2026 | Mark C. Schneyer | Sale | 9,292 | $29.34 |
| Aug 5, 2026 | Mark C. Schneyer | Sale | 5,849 | $29.00 |
| Aug 5, 2026 | Mark C. Schneyer | Sale | 5,849 | $29.00 |
| Aug 5, 2026 | Mark C. Schneyer | Sale | 5,849 | $29.00 |
| Aug 5, 2026 | Mark C. Schneyer | Sale | 5,849 | $29.00 |
| Jul 30, 2026 | Elizabeth H.Z. Thompson | Sale | 50 | $26.17 |
| Jul 30, 2026 | Elizabeth H.Z. Thompson | Sale | 16,508 | $26.13 |
| Jul 30, 2026 | Elizabeth H.Z. Thompson | Sale | 50 | $26.17 |
ACAD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.07B | $391.00M | 2.30 | $109.84M |
| Dec 31, 2024 | $957.80M | $226.45M | 1.36 | $157.72M |
| Dec 31, 2023 | $726.44M | $-61.29M | -0.37 | $16.70M |
| Dec 31, 2022 | $517.24M | $-215.97M | -1.34 | $-114.03M |
| Dec 31, 2021 | $484.14M | $-167.87M | -1.05 | $-125.66M |
Latest balance sheet: total assets $1.74B, total liabilities $436.29M, cash $384.99M (as of Jun 30, 2026).
ACAD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $27.15 |
| May 6, 2026 | 8-K Item 2.02 (results) | $21.48 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $24.97 |
| Jan 13, 2026 | 8-K Item 2.02 (results) | $26.46 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $22.33 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $23.80 |
| May 7, 2025 | 8-K Item 2.02 (results) | $14.81 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $19.00 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $15.79 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on ACAD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 1:16 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.